ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS - ) announced today that it intends to release its financial results for the quarter ended September 30, 2004 post-market on Thursday, November 11, 2004. The Company will also host a conference call with the investment community the same day at 5:00 p.m. ET.

To participate in the conference call, please dial 800.231.5571 (Domestic) or 973.582.2703 (International) a few minutes before 5:00 p.m. ET on Thursday, November 11, 2004. A replay of the conference call will be available from 7:00 p.m. ET on November 11, 2004 until 7:00 p.m. ET on November 18, 2004. The replay dial in number is 877.519.4471 (Domestic) or 973.341.3080 (International). The replay pin number is 5294249.

The call will also be available on the Internet live and for seven days thereafter at the following URL: http://phx.corporate-ir.net/playerlink.zhtml?c=179896&s=wm&e=959153

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire. All core components of the Stereotaxis System have received regulatory clearance in the U.S. and Europe.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward- looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

     Contacts:

     Stereotaxis, Inc.                       Euro RSCG Life NRP
     314-615-6957                            212-845-4253
     Jim Stolze, Chief Financial Officer     Ernie Knewitz (media)
     jstolze@stereotaxis.com                 ernie.knewitz@eurorscg.com

                                             212-845-4269
                                             Brian Ritchie (investors)
                                             brian.ritchie@eurorscg.com